686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2

Bibliographic Details
Main Authors: Tao Huang, An Song, Ryan Stafford, Maria Jose Costa, Zhiqiang Ku, Jing-Tyan Ma, Krista McCutcheon, Xiaoye Liu, Heyu Chen, Kyu Hong, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang, X Charlene Liao
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
_version_ 1818562683737210880
author Tao Huang
An Song
Ryan Stafford
Maria Jose Costa
Zhiqiang Ku
Jing-Tyan Ma
Krista McCutcheon
Xiaoye Liu
Heyu Chen
Kyu Hong
Ningyan Zhang
Zhiqiang An
Cheng Cheng Zhang
X Charlene Liao
author_facet Tao Huang
An Song
Ryan Stafford
Maria Jose Costa
Zhiqiang Ku
Jing-Tyan Ma
Krista McCutcheon
Xiaoye Liu
Heyu Chen
Kyu Hong
Ningyan Zhang
Zhiqiang An
Cheng Cheng Zhang
X Charlene Liao
author_sort Tao Huang
collection DOAJ
first_indexed 2024-12-14T01:06:59Z
format Article
id doaj.art-bb1d0a2138c845c9b062f11fd56be607
institution Directory Open Access Journal
issn 2051-1426
language English
last_indexed 2024-12-14T01:06:59Z
publishDate 2020-11-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj.art-bb1d0a2138c845c9b062f11fd56be6072022-12-21T23:22:57ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0686686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2Tao Huang0An Song1Ryan Stafford2Maria Jose Costa3Zhiqiang Ku4Jing-Tyan Ma5Krista McCutcheon6Xiaoye Liu7Heyu Chen8Kyu Hong9Ningyan Zhang10Zhiqiang An11Cheng Cheng Zhang12X Charlene Liao131Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA2University of Texas Health Science Center, Houston, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA3University of Texas Southwestern, Dallas, TX, USA3University of Texas Southwestern, Dallas, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA2University of Texas Health Science Center, Houston, TX, USA2University of Texas Health Science Center, Houston, TX, USA3University of Texas Southwestern, Dallas, TX, USA1Immune-Onc Therapeutics, Palo Alto, CA, USA
spellingShingle Tao Huang
An Song
Ryan Stafford
Maria Jose Costa
Zhiqiang Ku
Jing-Tyan Ma
Krista McCutcheon
Xiaoye Liu
Heyu Chen
Kyu Hong
Ningyan Zhang
Zhiqiang An
Cheng Cheng Zhang
X Charlene Liao
686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
Journal for ImmunoTherapy of Cancer
title 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
title_full 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
title_fullStr 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
title_full_unstemmed 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
title_short 686 Preclinical characterization of a novel therapeutic antibody targeting LILRB2
title_sort 686 preclinical characterization of a novel therapeutic antibody targeting lilrb2
work_keys_str_mv AT taohuang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT ansong 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT ryanstafford 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT mariajosecosta 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT zhiqiangku 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT jingtyanma 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT kristamccutcheon 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT xiaoyeliu 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT heyuchen 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT kyuhong 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT ningyanzhang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT zhiqiangan 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT chengchengzhang 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2
AT xcharleneliao 686preclinicalcharacterizationofanoveltherapeuticantibodytargetinglilrb2